Primary Immune Deficiencies

IV
Biotech

Takeda drug improves convenience for PID patients in pivotal trial

A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has demonstrated comparability to HyQvia.
Will Maddox May 4, 2026 10:48am
Spotlight

Bellicum touts promising T-cell therapy data

Mar 13, 2018 11:25am
Yale University campus - red building and a quadrangle with trees

X4 joins hands with Yale on rare disease program

Aug 2, 2017 9:25am